MedTrace Logo

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

NCT00521092 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-05-05

No results posted yet for this study

Summary

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.

Conditions

  • AIDS-related Kaposi Sarcoma
  • Classic Kaposi Sarcoma

Interventions

DRUG

sunitinib malate

Given orally

PROCEDURE

laboratory biomarker analysis

Correlative study

PROCEDURE

pharmacological study

Correlative study

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Scot Remick · Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00521092 on ClinicalTrials.gov